Overview
Gastric cancer (stomach cancer) ranks as the fifth most common cancer worldwide and the third leading cause of cancer-related mortality globally, claiming approximately 769,000 lives annually. Despite advances in systemic therapy and surgical technique, the majority of patients present with locally advanced or metastatic disease, where cure is rarely achievable.
Treatment is multimodal and increasingly biomarker-driven. Resectable disease is approached with perioperative FLOT chemotherapy (docetaxel, oxaliplatin, leucovorin, 5-FU) followed by total or subtotal gastrectomy with D2 lymphadenectomy. HER2-positive tumors (approximately 20% of gastric cancers) receive trastuzumab added to chemotherapy. PD-L1 positive or MSI-H tumors benefit from nivolumab (CHECKMATE 649), while VEGFR2 inhibition with ramucirumab addresses second-line progression. Emerging targets include FGFR2b (bemarituzumab) and claudin 18.2 (zolbetuximab).
Digital health platforms supporting gastric cancer programs must track HER2/PD-L1/MSI biomarker status, monitor complex post-gastrectomy nutritional deficiencies, manage endoscopic surveillance schedules, and coordinate multi-site chemotherapy administration. This guide describes how to architect and monitor those platforms effectively in 2026.
Care Technology Landscape
HER2 and Biomarker Status Dashboards
Gastric cancer treatment selection depends on HER2 IHC/FISH status, PD-L1 combined positive score (CPS), MSI/MMR status, and emerging biomarkers (FGFR2b, Claudin 18.2, EGFR). Molecular profiling platforms ingest IHC, FISH, and NGS results from pathology laboratories and surface them in an oncologist-facing biomarker summary dashboard. Monitoring ensures timely result availability before multidisciplinary tumor board review and treatment planning deadlines.
Post-Gastrectomy Nutritional Monitoring Platforms
Total gastrectomy eliminates intrinsic factor production, creating lifelong B12 malabsorption requiring parenteral replacement. Partial gastrectomy causes dumping syndrome, iron-deficiency anemia, and fat-soluble vitamin deficiencies. Nutritional monitoring platforms track serial laboratory values (B12, ferritin, iron saturation, albumin, pre-albumin), flag declining nutritional parameters, coordinate dietitian consultations, and manage parenteral B12 injection schedules. Dumping syndrome symptom tracking via patient-reported outcomes (PROs) captures quality-of-life data that informs dietary counseling.
Endoscopic Surveillance Schedulers
Patients with H. pylori-associated gastritis, intestinal metaplasia, hereditary diffuse gastric cancer (HDGC/CDH1 mutations), or prior endoscopic mucosal resection for early gastric cancer require structured endoscopic surveillance intervals. Scheduling platforms apply guideline-based intervals (e.g., AGA/ACG recommendations for intestinal metaplasia surveillance), automate patient outreach, coordinate pre-procedure bowel prep instructions, and track pathology results from surveillance biopsies.
Chemotherapy Administration and Dose Modification Platforms
FLOT and other gastric cancer regimens require careful cycle tracking, toxicity documentation, and dose modification logging. Pharmacy oncology systems (Beacon, Aria, iQPath) must integrate with the clinical oncology platform to surface ECOG performance status, weight changes, ANC/platelet counts, and renal function at each cycle to support dose calculation and modification decisions. Monitoring ensures no cycle is initiated without current lab verification.
Key Monitoring Metrics
Clinical Workflow Metrics
| Metric | Target | Alert Threshold | |---|---|---| | HER2/PD-L1 biomarker result turnaround | ≤7 days from specimen receipt | >10 days | | Time from diagnosis to multidisciplinary tumor board | ≤14 days | >21 days | | B12 injection administration adherence | >95% on schedule | <85% | | Post-gastrectomy B12 level monitoring frequency | Every 6 months | Missed interval >2 months | | Endoscopic surveillance overdue rate | <5% of active patients | >10% |
Platform Infrastructure Metrics
| Metric | Target | Alert Threshold | |---|---|---| | Biomarker result FHIR ingestion success rate | >99.5% | <99% | | Nutritional lab result LIS-to-platform latency | <10 minutes | >30 minutes | | Endoscopy scheduling system uptime | 99.9% | <99.5% | | Chemotherapy cycle verification API response time | <1 second | >3 seconds | | PRO survey push notification delivery rate | >95% | <85% |
Patient Safety Metrics
| Metric | Target | Alert Threshold | |---|---|---| | Post-gastrectomy patients with B12 <200 pg/mL without replacement order | 0 | Any | | HER2-positive patients without trastuzumab consideration documented | 0 | Any | | Patients with ferritin <10 ng/mL without iron supplementation | 0 | Any | | Chemotherapy cycle initiated without current CBC (<72h) | 0 | Any |
Platform Setup
1. Configure Biomarker Cascade Tracking
Set up automated tracking for the full gastric cancer biomarker panel from biopsy collection through result delivery. The platform should monitor every specimen through pathology processing stages and trigger alerts when expected results are overdue.
# Gastric cancer biomarker monitoring
biomarker_cascade:
required_tests:
- HER2_IHC
- HER2_FISH_if_IHC_2plus
- PD_L1_CPS
- MSI_IHC
- MMR_IHC
turnaround_targets_days:
HER2_IHC: 3
HER2_FISH: 7
PD_L1_CPS: 5
MSI_IHC: 5
alert_on_overdue: true
tumor_board_integration:
auto_populate_case: true
required_fields_before_presentation: [HER2, PD_L1_CPS, MSI]
2. Post-Gastrectomy Nutritional Surveillance Automation
Configure scheduled lab order sets at each post-gastrectomy follow-up visit (1 month, 3 months, 6 months, then annually) covering B12, folate, iron studies, CBC, albumin, and fat-soluble vitamins (A, D, E, K where indicated). Automate result review tasks for the registered dietitian and alerts for the treating oncologist when values fall outside safe ranges.
# Post-gastrectomy nutritional monitoring
nutritional_labs:
schedule_months: [1, 3, 6, 12, 18, 24]
panel:
- B12
- folate
- ferritin
- iron_saturation
- CBC
- albumin
- pre_albumin
- vitamin_D_25OH
alert_rules:
- lab: B12
threshold_low: 200
unit: pg/mL
action: [dietitian_task, physician_alert, b12_injection_order_suggestion]
- lab: ferritin
threshold_low: 10
unit: ng/mL
action: [dietitian_task, physician_alert]
- lab: albumin
threshold_low: 3.0
unit: g/dL
action: [dietitian_urgent_consult, physician_alert]
3. Dumping Syndrome PRO Monitoring
Deploy a structured PRO tool capturing early and late dumping symptoms (palpitations, sweating, cramping within 30 min of eating; hypoglycemia 1–3h post-meal) at each follow-up contact. Configure automatic dietitian referral when PRO scores exceed threshold, and track symptom trends longitudinally to assess dietary intervention effectiveness.
4. Endoscopic Surveillance Scheduling Engine
Implement a rules engine assigning surveillance intervals based on HDGC/CDH1 status, H. pylori treatment history, intestinal metaplasia grade, and prior EMR status. Integrate with the endoscopy procedure scheduling system to:
- Auto-generate referral orders when surveillance windows open
- Send patient outreach at 30 and 7 days before due dates
- Track biopsy results from surveillance procedures and update risk stratification
- Flag patients who decline or no-show for surveillance appointments
Alerting Strategies
Tiered Alert Classification
P1 – Immediate (page treating oncologist):
- B12 <100 pg/mL in post-gastrectomy patient with no replacement in past 90 days
- Chemotherapy cycle approved but lab values out of range (ANC <1,500 or plt <100k)
- HER2-positive patient approaching second-line therapy without trastuzumab contraindication documented
P2 – Urgent (notify within 4 hours):
- Biomarker results overdue with tumor board presentation scheduled within 48 hours
- Albumin <2.5 g/dL in patient actively receiving chemotherapy (toxicity risk)
- Endoscopic surveillance overdue >60 days for high-risk intestinal metaplasia patients
P3 – Advisory (daily or weekly digest):
- Overall post-gastrectomy nutritional lab completion rate below monthly target
- Endoscopic surveillance overdue rate trending upward in a clinic panel
- PRO survey non-response rate for dumping syndrome tracking above 30%
Integration with Multidisciplinary Tumor Board Workflow
Configure an automatic MTB readiness check 48 hours before each scheduled tumor board session. The check verifies that all required biomarker results are available for each case on the agenda and notifies the tumor board coordinator of any gaps, triggering escalated result requests from pathology or molecular labs.
Conclusion
Gastric cancer care tech platforms must navigate exceptional complexity: biomarker-driven treatment selection, profound post-surgical nutritional consequences, structured surveillance programs, and multi-agent chemotherapy logistics. Monitoring gaps in any of these domains directly affect patient outcomes and treatment quality.
Key priorities for 2026 gastric cancer platform operations:
- Biomarker cascade completeness to ensure HER2, PD-L1, and MSI results are available before every treatment decision
- Post-gastrectomy nutritional safety nets with automated B12 and iron deficiency detection and replacement prompting
- Endoscopic surveillance interval integrity to catch early recurrence and metachronous lesions in high-risk populations
- Chemotherapy cycle safety gates that prevent cycle initiation without current, within-range laboratory values
Vigilmon's monitoring and alerting infrastructure enables gastric cancer care teams to maintain visibility across this complex care pathway, ensuring that no patient falls through the gaps of a biomarker result delay, nutritional deficiency, or overdue surveillance examination.